Results 21 to 30 of about 3,796 (149)

The participation of the muscarinic receptors in the preoptic-anterior hypothalamic areas in the regulation of ovulation depends on the ovary

Reproductive Biology and Endocrinology, 2016
Background Muscarinic receptors (mAChRs) of the preoptic and anterior hypothalamus areas (POA-AHA) regulate ovulation in an asymmetric manner during the estrous cycle.
Adriana Espinosa-Valdez, Angélica Flores, Isabel Arrieta-Cruz, Mario Cárdenas, Roberto Chavira, Roberto Domínguez, María Esther Cruz   +6 more
doaj   +1 more source

Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer

Reproductive Biology and Endocrinology, 2003
The expression of GnRH (GnRH-I, LHRH) and its receptor as a part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary.
Emons Günter, Gründker Carsten
doaj   +1 more source

Involvement of Membrane Progestin Receptor Beta (mPRβ/Paqr8) in Sex Pheromone Progestin-Induced Expression of Luteinizing Hormone in the Pituitary of Male Chinese Black Sleeper (Bostrychus Sinensis)

Frontiers in Endocrinology, 2018
Our previous studies showed that 17α, 20β-dihydroxy-4-pregnen-3-one (DHP) acted as a sex pheromone to induce reproductive success in Chinese black sleeper (Bostrychus sinensis), but its functional mechanism remains unclear.
Yu Ting Zhang, Wan Shu Hong, Dong Teng Liu, Heng Tong Qiu, Yong Zhu, Yong Zhu, Shi Xi Chen, Shi Xi Chen, Shi Xi Chen   +8 more
doaj   +1 more source

AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

Expert Opinion on Investigational Drugs, 2012
Receptors for the luteinizing hormone-releasing hormone [LHRH, also known as gonadotropin-releasing hormone (GnRH)] can be regarded as an ideal target for a personalized medicine approach in cancer therapy. LHRH receptors are expressed in about 80% of human endometrial and ovarian cancers, 86% of prostate cancer, and about 50% of breast cancers ...
Engel, Joerg B., Emons, Guenter, Pinski, Jacek, Schally, Andrew V.   +3 more
openaire   +3 more sources

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

PLoS ONE, 2012
Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape--frequency and delay--are influenced by hormone therapy modalities.
Charlotte Guyader, Jocelyn Céraline, Eléonore Gravier, Aurélie Morin, Sandrine Michel, Eva Erdmann, Gonzague de Pinieux, Florence Cabon, Jean-Pierre Bergerat, Marie-France Poupon, Stéphane Oudard   +10 more
doaj   +1 more source

Prospective Short‐ and Long‐Term Changes in Cardiometabolic Risk Markers Following Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Introduction Gender‐affirming hormone therapy (GAHT) may be associated with increased cardiometabolic disease (CMD) risk. Prospective CMD risk screening is recommended, but long‐term data are needed regarding changes in CMD markers. Objectives To evaluate prospective changes in CMD risk markers during GAHT.
Louise Lehmann Christensen, Camilla Viola Palm, Marianne S. Andersen, Guy T'Sjoen, Jan Frystyk, Tine Taulbjerg Kristensen, Rikke Hjortebjerg, Dorte Glintborg   +7 more
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Changes in pituitary and ovarian LHRH receptors after active immunization of female rats against LH or LHRH [PDF]

Reproduction, 1985
Summary. The hypothalamic—pituitary—ovarian axis of female rats was disrupted at the site of LHRH stimulation by active immunization against LHRH or at the site of LH action by active immunization against LH. Active immunization against LH was associated with an increase in pituitary LHRH receptors to levels comparable to control ...
R M, Popkin, H M, Fraser
openaire   +2 more sources

The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology.
Sharon Nordheimer, Ofer N. Gofrit
wiley   +1 more source

Timing and Patterns of Relapse‐Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Early Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Adjuvant CDK4/6 inhibitors improve outcomes in hormone receptor‐positive, HER2‐negative (HR+/HER2−) early breast cancer, yet some patients still experience recurrence. Early relapse in particular is associated with poor prognosis, but the timing and patterns of recurrence following this treatment remain undefined, limiting further ...
Huihui Chen, Shijie Wu, Yangyang Shan, Xianan Guo, Wei Lu, Yiding Chen, Yunxiang Zhou   +6 more
wiley   +1 more source